- Trials with a EudraCT protocol (102)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
102 result(s) found for: coronavirus.
Displaying page 1 of 6.
| EudraCT Number: 2020-003628-18 | Sponsor Protocol Number: 000000 | Start Date*: 2020-09-29 | ||||||||||||||||
| Sponsor Name:University of Oxford, Clinical Trials and Research Governance | ||||||||||||||||||
| Full Title: Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial | ||||||||||||||||||
| Medical condition: COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-002110-41 | Sponsor Protocol Number: CRUKD/20/002 | Start Date*: 2020-06-18 | |||||||||||
| Sponsor Name:Cancer Research UK | |||||||||||||
| Full Title: SPIKE-1 TRIAL: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated memb... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001996-33 | Sponsor Protocol Number: CD12_COVID-19 | Start Date*: 2020-08-26 | |||||||||||
| Sponsor Name:CytoDyn, Inc. | |||||||||||||
| Full Title: A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (CO... | |||||||||||||
| Medical condition: Coronavirus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005280-31 | Sponsor Protocol Number: INHALAVID | Start Date*: 2021-04-21 | |||||||||||
| Sponsor Name:Fundació Eurecat | |||||||||||||
| Full Title: Phase IV, single-center, randomized and open-label study to evaluate the impact of early treatment with a combination of an inhaled corticosteroid and a long-acting β2 adrenergic agonist (budesonid... | |||||||||||||
| Medical condition: Enfermedad en pacientes vulnerables con COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001643-13 | Sponsor Protocol Number: 01.01.20 | Start Date*: 2020-05-15 | |||||||||||
| Sponsor Name:University of Dundee | |||||||||||||
| Full Title: A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001209-22 | Sponsor Protocol Number: PRINCIPLE | Start Date*: 2020-03-26 | |||||||||||
| Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
| Full Title: Platform Randomised trial of INterventions against COVID-19 In older peoPLE | |||||||||||||
| Medical condition: Suspected COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001441-39 | Sponsor Protocol Number: VIR20001 | Start Date*: 2020-05-12 | |||||||||||
| Sponsor Name:University of Oxford | |||||||||||||
| Full Title: Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) | |||||||||||||
| Medical condition: COVID-19, acute respiratory illness | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001338-21 | Sponsor Protocol Number: I4V-MC-KHAB | Start Date*: 2021-11-04 | |||||||||||
| Sponsor Name:Lilly S.A. | |||||||||||||
| Full Title: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19 | |||||||||||||
| Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001860-27 | Sponsor Protocol Number: UoL001542 | Start Date*: 2020-05-12 | |||||||||||
| Sponsor Name:University of Liverpool | |||||||||||||
| Full Title: AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment | |||||||||||||
| Medical condition: Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004719-28 | Sponsor Protocol Number: D8850C00003 | Start Date*: 2020-11-20 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005416-22 | Sponsor Protocol Number: GS-US-540-5912 | Start Date*: 2021-03-24 | |||||||||||
| Sponsor Name:Gilead Sciences Inc. | |||||||||||||
| Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who ... | |||||||||||||
| Medical condition: Coronavirus disease 2019 (COVID-19) in patients with chronic renal impairment | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PT (Completed) ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001803-17 | Sponsor Protocol Number: GS-US-540-5823 | Start Date*: 2020-07-14 | |||||||||||
| Sponsor Name:Gilead Sciences Inc. | |||||||||||||
| Full Title: A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19 | |||||||||||||
| Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001736-95 | Sponsor Protocol Number: ACCORD-2-001,Sub002,003,006 | Start Date*: 2020-04-28 | |||||||||||
| Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
| Full Title: ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients | |||||||||||||
| Medical condition: COVID 19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001934-37 | Sponsor Protocol Number: GLUCOCOVID | Start Date*: 2020-05-07 | |||||||||||
| Sponsor Name:IDIVAL Instituto de Investigación Sanitaria Valdecilla | |||||||||||||
| Full Title: USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 | |||||||||||||
| Medical condition: SARS-CoV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-002741-18 | Sponsor Protocol Number: GS-US-611-6273 | Start Date*: 2022-12-19 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression | |||||||||||||
| Medical condition: Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001031-27 | Sponsor Protocol Number: CQ4COV19 | Start Date*: 2020-03-14 | ||||||||||||||||
| Sponsor Name:FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA | ||||||||||||||||||
| Full Title: Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study) | ||||||||||||||||||
| Medical condition: SARS-CoV-2 Respiratory Viral Infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-001852-16 | Sponsor Protocol Number: 01-04-2020 | Start Date*: 2020-07-14 | |||||||||||
| Sponsor Name:Maxima MC | |||||||||||||
| Full Title: Effect of Iodine treatment in patiënts with COVID-19 disease | |||||||||||||
| Medical condition: SARS-CoV-2 infection causing COVID-19 disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001517-21 | Sponsor Protocol Number: I4V-MC-KHAA | Start Date*: 2020-06-30 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection | |||||||||||||
| Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001364-29 | Sponsor Protocol Number: AdiQure/COVID-19 | Start Date*: 2020-04-20 | |||||||||||||||||||||
| Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud | |||||||||||||||||||||||
| Full Title: Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia | |||||||||||||||||||||||
| Medical condition: Severe COVID-19 pneumonia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-004356-16 | Sponsor Protocol Number: D8850C00002 | Start Date*: 2020-11-18 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.